Biopharmaceutical company Lysogene announced on Wednesday that it had been placed in receivership by the Nanterre Commercial Court.

The gene therapy company, which specializes in diseases of the central nervous system, had been in safeguard proceedings since last month.

In the absence of a solution to consolidate its financial situation and secure its future financing, Lysogene, together with its insolvency administrator, had filed an application with the Nanterre Commercial Court to convert this safeguard procedure into a receivership procedure.

Now that this request has been approved, Lysogene would like to point out that a call for bids to find buyers or investors has been published, with a deadline for submission of bids set for February 15.

Copyright (c) 2023 CercleFinance.com. All rights reserved.